Q-omics provides the consensus-scored HTR2A profile across patient tissues and cancer cell-line models. HTR2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HTR2A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, HTR2A RNA expression shows 20,347 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, THCA, and GBM as cancer lineages where HTR2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR2A survival associations across molecular data types. HTR2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR2A RNA expression–survival associations across cancer types. High HTR2A expression shows unfavorable associations in KICH, STAD, LAML and SCLC, but favorable associations in LGG and LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for HTR2A RNA expression.
This table summarizes HTR2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HTR2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR2A shows lower tumor expression in THCA, BLCA, KICH, BRCA, UCEC and COAD. The THCA box plot shows higher HTR2A RNA expression in normal versus tumor tissue (log2 FC = −0.140, t-test p < 0.001).
This table shows molecular features associated with HTR2A in patient tissues and cancer cell lines. In patient samples, HTR2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
